15 September 2022
Latham & Watkins Advises on POINT Biopharma’s Common Stock Offering
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | corporate | Not stated |
| Peter Handrinos Lead | Latham & Watkins LLP | Partner | corporate | Not stated |
| Katie Byun | Latham & Watkins LLP | Associate | corporate | Not stated |
| Erin Gilgen | Latham & Watkins LLP | Associate | corporate | Not stated |
| Paul Rafla | Latham & Watkins LLP | Associate | corporate | Not stated |
| Danny Shulman | Latham & Watkins LLP | Associate | corporate | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 125m (US$125 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- POINT Biopharma Global Inc. (Issuer)